Immunocore(IMCR) - 2022 Q1 - Quarterly Report

Positive opinion from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP); KIMMTRAK regulatory submissions accepted for review in UK, Canada, and Australia Plan to report Phase 1 data from ImmTAC clinical candidates targeting PRAME (3Q 2022) and MAGE-A4 (4Q 2022) in multiple solid tumors this year Cash position of approximately $321 million as of December 31, 2021 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 March 2022) Immunocore Holdings plc (Nasdaq: IM ...